Cagrilintide

Cagrilintide

Cagrilintide is a long-acting amylin analogue developed for preclinical investigation of metabolic regulation, appetite control, and body weight modulation. As a synthetic analogue of human amylin, it is designed to resist enzymatic degradation and provide sustained receptor engagement, making it a valuable tool compound for studying amylin receptor biology and its role in energy homeostasis. Cagrilintide has been investigated in combination with GLP-1 receptor agonists for its additive effects on satiety and metabolic parameters.

Mechanism of Action

Cagrilintide acts as an agonist at amylin receptors (AMY1, AMY2, AMY3), which are heterodimeric complexes of the calcitonin receptor and receptor activity-modifying proteins (RAMPs). Activation of these receptors in the hypothalamus and brainstem suppresses appetite, slows gastric emptying, and reduces postprandial glucagon secretion. Its extended half-life relative to native amylin is achieved through fatty acid conjugation, enabling once-weekly dosing paradigms in research models.

Research Applications

• Amylin receptor pharmacology and signalling studies
• Appetite regulation and satiety pathway investigation
• Metabolic syndrome and obesity modelling
• Combination peptide therapy research (e.g. with GLP-1 analogues)
• Gastric motility and postprandial glucagon studies

Specifications

• Molecular Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
• CAS Number: 2173044-15-8
• Purity: ≥98%
• Molecular Weight: 4421.1 g/mol
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.